In a consortium allying a Mass Spectrometry platform, a cancer biology lab, several clinicians, and a bioinformatic team, we investigated how epigenetic marks on the RNA (a.k.a., the epitranscriptome) can help distinguishing the different grades of glioma tumors from tissue samples. We came up with a pipeline that proceeds surgical samples, measures the level of epitranscriptomic marks, and predicts the grade of this cancer. Our method delivers grade prediction with unmet sensitivity and specificity.